---
schema_version: "secwatch.filing_event.v1"
accession: "0001645666-25-000026"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T16:12:27.490593+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# KZR Q1 2025 net loss $16.6M; positive PORTOLA data in AIH

## Summary
- Cash $114.4M at March 31, 2025, down from $132.2M at Dec 31, 2024.
- Net loss $16.6M ($2.27/share) vs $21.7M ($2.98) in Q1 2024.
- PORTOLA Phase 2a: 36% zetomipzomib patients achieved CR with steroid taper vs 0% placebo in relapsed AIH.
- R&D expenses fell $5.0M to $12.2M due to PALIZADE trial termination.
- Responding to FDA partial clinical hold on PORTOLA; no flares in CR patients.

## SEC filing metadata
- accession: 0001645666-25-000026
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000164566625000026/0001645666-25-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000164566625000026/kzr-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645666-25-000026
- JSON: https://secwatch.observer/filing/0001645666-25-000026.json
- Plain text: https://secwatch.observer/filing/0001645666-25-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.